Literature DB >> 25144401

DNA fragment conformations in adducts with Kiteplatin.

Nicola Margiotta1, Emanuele Petruzzella, James A Platts, Shaun T Mutter, Robert J Deeth, Rosa Ranaldo, Paride Papadia, Patricia A Marzilli, Luigi G Marzilli, James D Hoeschele, Giovanni Natile.   

Abstract

The anticancer activity of cisplatin is triggered by its formation of intrastrand adducts involving adjacent G residues of DNA. To obtain information on the different conformers that can be formed, carrier ligands such as 2,2'-bipiperidine, which provide large steric bulk near the platinum coordination plane and decrease the dynamic motion about the Pt-N7 bonds, were introduced ("retro-modelling" approach). In the present study we investigate the effect of cis-1,4-diaminocyclohexane (cis-1,4-DACH) on the formation, stability, and stereochemistry of (cis-1,4-DACH)Pt(ss-oligo) adducts (ss-oligo = d(GpG) with 3'- and/or 5'-substituents). Interesting features of this ligand, absent in previous retro-modelling studies, include the large bite angle (expected to impede the ease of interconversion between possible conformers), the presence of two protons on each nitrogen (a characteristic associated with antitumor activity), and the absence of chiral centres. The use of cis-1,4-DACH has made it possible to detect different conformers in a system containing a primary diamine carrier ligand associated with anticancer activity and to confirm the previous hypothesis that the coexistence of different conformers established in studies of retro models having relatively bulky ligands is not an artefact resulting from carrier-ligand bulk. Moreover, the data for the (cis-1,4-DACH)Pt(d(GpG)) and (cis-1,4-DACH)Pt(d(GGTTT)) adducts indicate that at a temperature close to the physiological one (40 °C) HH1 and ΔHT1 conformers are present in comparable amounts. In contrast, at low temperature (close to 0 °C) the equilibrium shifts dramatically toward the more stable HH1 conformer (for the (cis-1,4-DACH)Pt(d(TGGT)) adduct the HH1 conformer is always dominant, even at high temperature). Notably, (cis-1,4-DACH)PtCl2 (Kiteplatin) has been recently reinvestigated and found to be particularly active against colorectal cancer (including oxaliplatin-resistant phenotypes).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25144401     DOI: 10.1039/c4dt01796j

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  3 in total

1.  Computational evidence for structural consequences of kiteplatin damage on DNA.

Authors:  Shaun T Mutter; Nicola Margiotta; Paride Papadia; James A Platts
Journal:  J Biol Inorg Chem       Date:  2014-11-07       Impact factor: 3.358

2.  Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration.

Authors:  Alessandra Barbanente; Valentina Gandin; Cecilia Ceresa; Cristina Marzano; Nicoletta Ditaranto; James D Hoeschele; Giovanni Natile; Fabio Arnesano; Concetta Pacifico; Francesco P Intini; Nicola Margiotta
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

3.  A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring.

Authors:  Paride Papadia; Valentina Gandin; Alessandra Barbanente; Alessandro G Ruello; Cristina Marzano; Katia Micoli; James D Hoeschele; Giovanni Natile; Nicola Margiotta
Journal:  RSC Adv       Date:  2019-10-11       Impact factor: 3.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.